PCN75 Cost-Minimization and Budget Impact Analysis of Venetoclax plus Obinutuzumab versus Ibrutinib in High-Risk Patients with Untreated Chronic Lymphocytic Leukemia in the Brazilian Unified Health System (SUS)
Abstract
Authors
M.E.Z. Capra R. Pereira Pinto C. Brito Filho A. Travassos